Results 131 to 140 of about 8,886,396 (384)

Targeting the MDM2‐MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini   +10 more
wiley   +1 more source

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters

open access: yesBioDrugs, 2015
The purpose of making a “biobetter” biologic is to improve on the salient characteristics of a known biologic for which there is, minimally, clinical proof of concept or, maximally, marketed product data.
W. Strohl
semanticscholar   +1 more source

Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors

open access: yesMolecular Oncology, EarlyView.
Combining melting curve analysis enhances the multiplexing capability of digital PCR. Here, we developed a 14‐plex assay to simultaneously measure single nucleotide mutations and amplifications of KRAS and GNAS, which are common driver genes in pancreatic cancer precursors. This assay accurately quantified variant allele frequencies in clinical samples
Junko Tanaka   +10 more
wiley   +1 more source

Comment on "Precise half-life values for two-neutrino double beta decay"

open access: yes, 2010
The results by A.S. Barabash [Phys. Rev. {\bf C 81}, 035501 (2010)] are shown to be incomplete. Tellurium data sets were reanalyzed using the best practices of ENSDF evaluations.
Pritychenko, B.
core   +1 more source

The half-life of the first excited state of 111Cd [PDF]

open access: green, 1955
L.H.Th. Rietjens   +2 more
openalex   +1 more source

Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII

open access: yesJournal of Thrombosis and Haemostasis, 2017
Essentials Recombinant factor VIII BAY 94‐9027 conjugates in a site‐specific manner with polyethylene glycol. BAY 94‐9027 was given to patients with severe hemophilia A as prophylaxis and to treat bleeds. BAY 94‐9027 prevented bleeds at dose intervals up
M. Reding   +10 more
semanticscholar   +1 more source

A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression‐free survival

open access: yesMolecular Oncology, EarlyView.
There is an unmet need in metastatic breast cancer patients to monitor therapy response in real time. In this study, we show how a noninvasive and affordable strategy based on sequencing of plasma samples with longitudinal tracking of tumour fraction paired with a statistical model provides valuable information on treatment response in advance of the ...
Emma J. Beddowes   +20 more
wiley   +1 more source

Electron capture half-life of 243Cm [PDF]

open access: green, 1958
Gregory R. Choppin, S.G. Thompson
openalex   +1 more source

Home - About - Disclaimer - Privacy